I usually don't buy into penny stocks but I am interested in new technology that has a niche.
The cost of entering those niches are so expensive and when someone comes up with a new way of solving problems then they become a buyout candidate.
Most penny stocks in this category do not make money. This stock does which is even more attractive.
I’ve been predicting for some time that we will begin to blur the lines between human and machine. It will be innocuous, as people will augment their bodies with computers and sensors. An artificial eye is coming soon.

PLC Medical Systems Inc. (PLC: AMEX) announced the enrollment of the first patients in its FDA-approved clinical trial for RenalGuard. RenalGuard is designed to reduce contrast-induced nephropathy (CIN) by managing real-time fluid balance during surgical and related procedures where contrast media are administered. Dr. Richard B. Zelman at Cape Cod Hospital in Hyannis, Mass., performed the tests.

"The use of Renal Guard Therapy maintained a high level of urine output, which is believed to reduce potential renal toxicity by protecting the kidney during interventional cardiac procedures requiring contrast media," said Dr. Zelman. "The system operated smoothly and did not change the flow of the catheterization procedure. The patients' procedures were completed successfully and the patients experienced no adverse renal complications."

CIN is a serious and little-recognized problem that is a side effect of the best new ways of diagnosing certain deadly conditions. By preventing this from causing kidney failure, PLC is making it possible for contrast media to be used not only more safely, but also more aggressively.

This is sure to lead to widespread adoption once safety is proven. These initial results are encouraging, but not surprising.

Action to take: As a special situation, buy PLC Medical Systems Inc. (PLC:
AMEX) at 60 cents or better. As always, plan to hold your shares for years, not months, and do not chase the price.